ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / MDT / insiders
LIVN (68) ITGR (67) AXGN (54) TMDX (62) ⌘ Pro Terminal β†’

Medtronic plc. (MDT) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$96.54 -0.59% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $96.67

Medtronic plc. (MDT) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (65% profit margin, 8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY β€’ 68.7% hit rate) β†’
ROARABLE B β€’ BUY Cap $124.22B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MDT Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is MDT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Medtronic plc. (NYSE: MDT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $96.54 (-0.59% 1D, market cap $124.22B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MDT ranks #63 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does MDT compare to LIVN and ITGR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), MDT carries a Roarable B (72/100 RQD), trailing P/E of N/A, gross margin of 65.0%, and ROIC of 7.8%. By comparison, LIVN (LivaNova PLC) holds a C+ grade (68/100 RQD, P/E N/A, ROIC 17.3%, cap $4.48B) and ITGR (Integer Holdings Corporation) posts a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MDT?
β–Ό

Per MDT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-24, CIK 0001613103), Medtronic plc. generated $36.36B in revenue (+8.4% YoY), $4.8K in net income, and $5.43B in free cash flow against $91.48B in total assets and $19.03B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $96.67 (+0.13%)🧬 Cannibal Buyback (-1.52% YoY Shares)βš™οΈ Cash Engine: 13/20 (C) β€’ 14.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY β€’ 68.7% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B Β· Rk B
Cash (13)Whales (17)SEC (16)Macro (13)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$121 Bull$103 Base$79 Bear
πŸ“¬ FREE MDT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for MDT)Realized 20D OHLCV Swing Band: Β±5.3%
Deterministic 5-Pillar Attribution (72/100 Composite)
πŸ” WHY MDT SCORES 72/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)

20D Institutional Volume Accumulation (Β±5.3% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 3.08 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution13/20 pts (-7 pt drag)

Cannibal Buyback (-1.52% YoY Shares) & executive Form 4 sales trim 7 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
64
Grade C+$93.01+1.7% Next Q
Q2 (-2Q)
67
Grade B-$94.63-0.7% Next Q
Q3 (-1Q)
69
Grade B-$93.95+2.8% Next Q
Current
72
Grade B$96.54+7% Hist 90D Ξ±
Trajectory: C+ (64) β†’ B (72)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the MDT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 72/100 (B) score, MDT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) β€” any gross margin slip below 62.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($91.86) or 200D SMA ($88.15) invalidates the momentum regime and cuts Target Base ($102.62) toward Bear Floor ($79.16).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MDTβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œMDT Beats Next Quarter EPS Consensus (Jan 22, 2027) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

MDT Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MDT)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MDT. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (MDT Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
MDT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.30%⚑ TESTING RESISTANCE
2026-11-02O $94.78H $97.11L $94.78C $96.54VOL 9.38M
RES: $98.22SUP: $87.61SMA50: $91.86SMA200: $88.15
$99.82$92.64$85.45$78.27$71.08RES $98.22SUP $87.61$96.542026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MDT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ MDT Butterfly Map β†’ + Track MDT β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
15.5%/yr Implied 5Y Growth

vs. +8.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MDT today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for MDT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MDT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDT)

Health Care Rank #63 of 1016 βš”οΈ LIVN vs MDT Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (MDT vs. LIVN, ITGR, AXGN, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Medtronic plc. (MDT) ranks #63 by composite RQD confidence (72/100, grade B) and #19 by equity capitalization ($124.22B). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. MDT currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MDT ACTIVE
Medtronic plc.
B 72/100 β€” 65.0% 7.8% -0.59% $124.22B Benchmark Subject
LIVN
LivaNova PLC
C+ 68/100 β€” 67.7% 17.3% -2.81% $4.48B /livn-vs-mdt β†’
ITGR
Integer Holdings Corporation
C+ 67/100 41.8x 27.0% 6.0% +0.06% $4.30B /itgr-vs-mdt β†’
AXGN
Axogen Inc.
D+ 54/100 β€” 74.3% -2.6% -0.52% $2.96B /axgn-vs-mdt β†’
TMDX
TransMedics Group Inc.
C 62/100 12.2x 59.9% 18.1% -1.68% $2.33B /tmdx-vs-mdt β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-04-24 β€’ CIK 0001613103

In its most recent audited fiscal period (FY2025, filed 2026-04-24), Medtronic plc. (MDT) reported GAAP revenue of $36.36B (+8.4% vs. FY2024 revenue of $33.54B , and +12.4% cumulative change since FY2023) , GAAP net income of $4.8K, operating cash flow of $7.33B, and free cash flow of $5.43B (+4.6% YoY). On the balance sheet, MDT closed FY2025 with $91.48B in total assets against $19.03B in total debt (Altman Z-Score: 3.08, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-24 $36.36B $4.8K $7.33B $5.43B $91.48B $19.03B
FY2024 (FY) 2025-04-25 $33.54B $4.7K $7.04B $5.18B $89.97B $18.16B
FY2023 (FY) 2024-04-26 $32.36B $3.7K $6.79B $5.33B $68.32B $15.99B

3. MDT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MDT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Medtronic plc. (NYSE: MDT) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $96.54 (-0.59% 1D, market cap $124.22B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MDT ranks #63 in composite RQD confidence.

How does MDT compare to LIVN and ITGR in the Health Care sector?

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), MDT carries a Roarable B (72/100 RQD), trailing P/E of N/A, gross margin of 65.0%, and ROIC of 7.8%. By comparison, LIVN (LivaNova PLC) holds a C+ grade (68/100 RQD, P/E N/A, ROIC 17.3%, cap $4.48B) and ITGR (Integer Holdings Corporation) posts a C+ grade (67/100 RQD, P/E 41.8x, ROIC 6.0%, cap $4.30B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MDT?

Per MDT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-24, CIK 0001613103), Medtronic plc. generated $36.36B in revenue (+8.4% YoY), $4.8K in net income, and $5.43B in free cash flow against $91.48B in total assets and $19.03B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MDT trading relative to its 50-day, 200-day, and 52-week technical levels?

MDT last traded at $96.54 (-0.59% on volume of 8,682,971 shares), positioning the stock +5.09% above its 50-day simple moving average ($91.86) and +9.52% above its 200-day simple moving average ($88.15). Across its 52-week range of $73.31 to $106.33, MDT sits at the 70.4% percentile with a 14-day RSI of 61.8 (BULLISH MOMENTUM) and an implied next-earnings move of Β±5.3% ($91.42 to $101.66).

MDT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are MDT insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies MDT leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: MDT RQD Cockpit MDT 12M Forecast MDT Earnings & Move MDT Dividends & DRIP MDT Insiders & 13F MDT Whale Options MDT Profit Sankey MDT News & Why
ROARABLE RATING BRIEF β€’ RQD 72/100 (B) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

MDT β€” Medtronic plc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:09:30Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MDT scores 72 out of 100, a letter grade of B, with the verdict label "Roarable Buy β€” Good Risk/Reward." The score is built from five pillars:

  • Fundamental Cash Engine: 13 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 7.8% and an FCF yield of 4.37%. Per the market data, ROIC is 7.8% and FCF yield is 4.37%. For an investor, this indicates the business generates cash relative to its market value, but its return on invested capital is modest and the cash yield is the main valuation anchor rather than an earnings-based multiple.
  • Whale 13F Flow: 17 / 20. Per the Roarable RQD rating, this is the strongest pillar and captures institutional accumulation and options positioning. The source data does not itemize the underlying 13F filings, so the magnitude of this accumulation cannot be verified here. This is the highest-weighted pillar and is an upside driver if sustained.
  • Insider Conviction: 13 / 20. Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The <holders> section is empty in the source data, so the specific trades behind this score are not available in source data.
  • Macro Regime Fit: 13 / 20. Per the Roarable RQD rating and market data, beta is 0.91, indicating below-market sensitivity to broad market moves. This offers relative stability in volatile regimes but limits upside participation in strong rallies.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 3.08, Piotroski F is 9/9, and Debt/Equity is 0.36. These are strong forensic readings and reduce solvency concern.

Investor implications: the rating reflects a combination of institutional support and a sound balance sheet, offset by a modest ROIC and a valuation anchored on cash yield. Per the market data, EV/EBITDA is 17.4, which is a valuation tradeoff to weigh against the rating. Per the news wire, the stock has been described in a headline as having had a 36% run, so entry timing relative to recent price appreciation is a relevant consideration. This is educational analysis, not personalized advice.

Business

Medtronic plc. (MDT) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry. Per the profile, the company has a market capitalization of $124.2B. The source data does not describe its specific product lines, customer segments, or revenue model beyond the sector and industry classification. Gross margin is reported at 65% and operating margin at 17.8% per the market data.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$36364.0M$6467.0M$0.0MN/A$5426.0M$1147.0M$19030.0M
FY 2024$33537.0M$5955.0M$0.0MN/A$5185.0M$1240.0M$18161.1M
FY 2023$32364.0M$5144.0M$0.0MN/A$5330.6MN/A$15986.7M

Per the SEC financials, revenue rose from $32364.0M (FY 2023) to $36364.0M (FY 2025), and operating income rose from $5144.0M to $6467.0M over the same span. Reported net income is $0.0M in each period, and the market data lists net margin at 0%, so the source data does not support a profitability conclusion from net income. Per the Roarable RQD rating, Altman Z is 3.08 and Piotroski F is 9/9, indicating a strong forensic profile. Debt rose from $15986.7M to $19030.0M across the periods, and Debt/Equity is reported at 0.36 per the Roarable RQD rating.

Recent Catalysts & News Wire Analysis

Per the news wire, several items relate to a MiniMed transaction:

  • A report that the MiniMed split-off could stall, with a question about implications for MDT shareholders (Trefis, YELLOW).
  • A report that the MiniMed exchange offer was oversubscribed with an 18.3% acceptance rate (Seeking Alpha, YELLOW).
  • A Medtronic release on preliminary results of the MiniMed Group, Inc. exchange offer (YELLOW).

Other items include a headline describing a 36% run in the stock (Yahoo Finance, GREEN, CATALYST), a Motley Fool piece on approaching dividend-king status, and a Yahoo Finance piece on valuation at 14x earnings. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals in source data.

Open Questions

  • What is the composition and magnitude of the institutional 13F accumulation underlying the 17/20 whale pillar?
  • What are the specific SEC Form 4 and Congressional PTR trades behind the insider pillar score?
  • What are the reported EPS and net income figures, given that the source shows N/A and $0.0M across periods?
  • What is the status and timing of the MiniMed split-off or exchange offer, and what is its effect on remaining MDT shareholders?
  • What is the analyst consensus and price target range, given that no analyst data is provided?

MDT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medtronic plc. (MDT) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to MDT Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MDT Bull vs. Bear Conversation Board β€” What's Your Call at $96.54?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MDT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MDT:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $114.59 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is MDT (B β€’ RQD 72/100) a Buy at $97.11?

Welcome to the MDT (Medtronic plc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy β€” Good Risk/Reward) in Biotechnology: Electromedical & Electrotherapeutic Apparatus. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $76.72 (-21.0%)
Spot @ $97.11

Pump the brakes on MDT β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MDT, but look at what you are paying: current EV/EBITDA multiples with 65.0% gross margins. Unless Medtronic plc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $120.42 (+24.0%)
Spot @ $97.11

MDT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MDT, the market is fixating on short-term headline noise in Biotechnology: Electromedical & Electrotherapeutic Apparatus and ignoring the balance sheet and cash flow trajectory. At $97.11 (52-wk range $73.31 - $106.33), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%